ALLMedicine™ Lymphomas Center
Research & Reviews 8,061 results
The American Journal of Dermatopathology; Silveira HA, Ragusa Silva PV et. al.
Mar 21st, 2023 - Lymphomatoid papulosis (LyP) belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders, characterized by chronic, recurrent, self-healing papules, small nodules, or ulcers. The clinicopathological features of LyP can mimic o...
Cancer Discovery; Schroers-Martin JG, Soo J et. al.
Mar 21st, 2023 - Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals suggesting additional lesions are required for lymphomagenesis. We directly cha...
AIDS (London, England); Vargas JC, Marques MO et. al.
Mar 21st, 2023 - To analyze the factors associated with survival in the largest cohort of individuals with HIV and lymphoma so far described in Brazil. A retrospective, observational, multicenter study involving five institutions in São Paulo, Brazil. The medical ...
Otolaryngology--head and Neck Surgery : Official Journal ... Peng J, Qiu J et. al.
Mar 21st, 2023 - We aimed to compare clinical and survival differences between B-cell (B-NHL) and NKT-cell non-Hodgkin lymphomas (NKT-NHL) located in the nasal cavity (NC), nasopharynx, and paranasal sinuses, which are always categorized as one sinonasal type. Pat...
Nature Communications; Portelinha A, da Silva Ferreira M et. al.
Mar 20th, 2023 - Spontaneous whole genome duplication and the adaptive mutations that disrupt genome integrity checkpoints are infrequent events in B cell lymphomas. This suggests that lymphomas might be vulnerable to therapeutics that acutely trigger genomic inst...
Guidelines 24 results
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.
Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...
Annals of Diagnostic Pathology; Vega F, Amador C et. al.
Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.
Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.
Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.
Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...
Drugs 541 results see all →
Clinicaltrials.gov 896 results
Mar 13th, 2023 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...
Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with AG-120 (ivosidenib) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas...
Mar 10th, 2023 - Background: The treatment of the intermediate and aggressive non-Hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to hav...
Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with larotrectinib sulfate (LOXO-101 [larotrectinib]) with advanced solid tumors (including central nervous sy...
Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with samotolisib (LY3023414) with advanced solid tumors, non-Hodgkin lymphomas or central nervous system (CNS)...
News 1,747 results
Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...
Jessica Joanne Padniewski, DO, Shoshana Blumenthal, MD et. al.
Mar 1st, 2023 - The Diagnosis: Plasmablastic Lymphoma A punch biopsy of one of the leg nodules with hematoxylin and eosin staining revealed sheets of medium to large cells with plasmacytic differentiation (Figure, A and B). Immunohistochemistry showed CD79, epith.
Michael E. Williams, MD, ScM
Mar 1st, 2023 - Mantle cell lymphoma (MCL) has served as a paradigm of progress among the non-Hodgkin lymphomas over the past 30 years. It was originally defined within the Kiel classification as centrocytic lymphoma, then renamed MCL once the characteristic tran.
Jan 30th, 2023 - A woman in her late 40s presented with painful ulcers in her groin and armpits that hadn't healed in 3 years, an Indian group reported in JAMA Dermatology. The woman explained that when the sores first appeared, they were just itchy, oozing, reddi...
Jan 26th, 2023 - Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2) inhibitor milademeta...